person · Reporting owner

MARIO ERNEST

Disclosed activity across 7 companies

Tapewire entity: 90102
SEC CIK: 0001180469

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CHIMERIX INCCMRX · Entity 80651	Director	May 17, 2018	May 21, 2018
HYPERION DEFI, INC.EYEN · Entity 7220	Director	November 17, 2021	November 22, 2021
Jasper Therapeutics, Inc.AMHCU · Entity 7588	Director	November 19, 2019	November 19, 2019
Kindred Biosciences, Inc.KIN · Entity 135544	Director	January 20, 2021	January 22, 2021
SOLENO THERAPEUTICS INCSLNO · Entity 46432	Director	June 06, 2024	June 10, 2024
Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169	Director	June 25, 2018	June 27, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CHIMERIX INC

Report date May 17, 2018 · Filed May 21, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees	123,167	Reported balance After 2018-05-17 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-05-17 · Sale · Disposed 30,000 · Balance 123,167 F1: The range of sale prices received is $4.73 to $4.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
Common StockSEC Table I · non-derivative	IndirectBy The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees	108,167	Reported balance After 2018-05-18 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-05-18 · Sale · Disposed 15,000 · Balance 108,167 F2: The range of sale prices received is $4.76 to $4.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
Common StockSEC Table I · non-derivative	Direct	12,905	Reported balance Holding disclosure · report date 2018-05-17 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 12,905

Filing footnotes · ownership attribution and instrument terms

F1: The range of sale prices received is $4.73 to $4.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.

F2: The range of sale prices received is $4.76 to $4.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.

HYPERION DEFI, INC.

Report date November 17, 2021 · Filed November 22, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.0001SEC Table I · non-derivative	Direct	382,706	Reported balance After 2021-11-17 transaction · row 1 1 source row Row 1 · 2021-11-17 · Grant · Acquired 6,963 · Balance 382,706 F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2031-11-17	Direct	9,653	Reported balance After 2021-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-11-17 · Grant · Acquired 9,653 · Balance 9,653 F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.

F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.

Jasper Therapeutics, Inc.

Report date November 19, 2019 · Filed November 19, 2019

This filing explicitly reported no securities owned.

Kindred Biosciences, Inc.

Report date January 20, 2021 · Filed January 22, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2031-01-19	Direct	49,000	Reported balance After 2021-01-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-01-20 · Grant · Acquired 49,000 · Balance 49,000 F1: The option will vest in four equal quarterly installments from the option grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in four equal quarterly installments from the option grant date.

SOLENO THERAPEUTICS INC

Report date June 06, 2024 · Filed June 10, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	193,066	Reported balance After 2024-06-06 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-06-06 · Grant · Acquired 6,500 · Balance 193,066 F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. F2: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
Common StockSEC Table I · non-derivative	IndirectSee footnote	21,789	Reported balance Holding disclosure · report date 2024-06-06 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 21,789 F3: The shares are held by Mildred Mario Nonexempt Trust, of which the Reporting Person is a co-trustee.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date.

F2: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

F3: The shares are held by Mildred Mario Nonexempt Trust, of which the Reporting Person is a co-trustee.

Tonix Pharmaceuticals Holding Corp.

Report date June 25, 2018 · Filed June 27, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	IndirectBy Ernest and Mildred Mario Revocable Trust	50,000	Reported balance After 2018-06-25 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-06-25 · Purchase · Acquired 16,500 · Balance 50,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.46 to $4.52 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.46 to $4.52 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-11-20 transaction · row 1 1 source row Row 1 · 2019-11-20 · Disposition to issuer · Disposed 62,884 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Common StockSEC Table I · non-derivative	IndirectFamily Trust	Reported balance After 2019-11-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-11-20 · Disposition to issuer · Disposed 4,908 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.50 · Expires 2024-07-01	Direct	Reported balance After 2019-11-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-20 · Disposition to issuer · Disposed 20,700 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17	Direct	Reported balance After 2019-11-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15	Direct	Reported balance After 2019-11-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14	Direct	Reported balance After 2019-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13	Direct	Reported balance After 2019-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-20 · Disposition to issuer · Disposed 300 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-11-20 · Disposition to issuer · Disposed 970 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.

F2: This option was fully exercisable.

F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 06, 2024 Filed Jun 10, 2024 20:49 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	6,500	$0.00	$0.00	Disclosure SEC source: 0001415889-24-016309 · form4-06112024_120602.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,066 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document
May 21, 2024 Filed May 23, 2024 19:11 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	OtherWarrant (right to buy) · Derivative	62,000	$0.00 Strike: $4.50	$0.00	Disclosure SEC source: 0001415889-24-014389 · form4-05232024_110501.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,000 shares Expires 2027-03-31 Read SEC document
May 21, 2024 Filed May 23, 2024 19:11 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	OtherCommon Stock	62,000	$4.50	$279,000.00	Disclosure SEC source: 0001415889-24-014389 · form4-05232024_110501.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,566 Read SEC document
January 08, 2024 Filed Jan 10, 2024 16:31 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GiftCommon Stock	3,523	$0.00	$0.00	Disclosure SEC source: 0001209191-24-001353 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,566 Read SEC document
November 30, 2023 Filed Dec 4, 2023 20:41 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GiftCommon Stock	8,700	$0.00	$0.00	Disclosure SEC source: 0001209191-23-057329 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,089 F1 · balance_after: The number of shares held directly no longer includes 20,752 shares which are now reported below as held by Mildred Mario Nonexempt Trust, of which the Reporting Person is a co-trustee. F2 · balance_after: The number of shares beneficially owned has been reduced by one share pursuant to an internal review of the Reporting Person's holdings. Read SEC document
May 26, 2023 Filed May 26, 2023 18:29 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock option (right to buy) · Derivative	10,000	$0.00 Strike: $5.25	$0.00	Disclosure SEC source: 0001209191-23-032695 · doc4.xml · derivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-26 F2 · derivative.exercise_date: The shares subject to the Option shall vest on November 26, 2023, subject to the Reporting Person continuing to be a Service Provider through such date. Read SEC document
May 25, 2023 Filed May 26, 2023 18:29 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock option (right to buy) · Derivative	2,666	$0.00 Strike: $5.03	$0.00	Disclosure SEC source: 0001209191-23-032695 · doc4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 2,666 shares Expires 2033-05-25 F1 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of May 25, 2023 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. Read SEC document
June 01, 2022 Filed Oct 14, 2022 18:29 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock option (right to buy) · Derivative	2,666	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001209191-22-053696 · doc4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 2,666 shares Expires 2032-06-01 F1 · derivative.exercise_price: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F1 · shares: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F2 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date. F1 · derivative.underlying_shares: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F1 · balance_after: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. Read SEC document
March 31, 2022 Filed Apr 4, 2022 16:07 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseWarrant (right to buy) · Derivative	930,000	Not disclosed Strike: $0.30	Not disclosed	Disclosure SEC source: 0000899243-22-013315 · doc4.xml · derivative · entry 4 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 930,000 Underlying: Common Stock · 930,000 shares Expires 2027-03-31 F1 · price: Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25. F2 · ownership.nature: The securities are held by Mario 1998 Irrevocable Trust, of which Dr. Mario is the ultimate beneficiary. Read SEC document
March 31, 2022 Filed Apr 4, 2022 16:07 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseWarrant (right to buy) · Derivative	930,000	Not disclosed Strike: $0.30	Not disclosed	Disclosure SEC source: 0000899243-22-013315 · doc4.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930,000 Underlying: Common Stock · 930,000 shares Expires 2027-03-31 F1 · price: Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25. Read SEC document
March 31, 2022 Filed Apr 4, 2022 16:07 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseCommon Stock	930,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-013315 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 930,000 F1 · price: Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25. F2 · ownership.nature: The securities are held by Mario 1998 Irrevocable Trust, of which Dr. Mario is the ultimate beneficiary. Read SEC document
March 31, 2022 Filed Apr 4, 2022 16:07 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseCommon Stock	930,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-013315 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,363,135 F1 · price: Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25. Read SEC document
January 31, 2022 Filed Feb 2, 2022 20:52 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	56,338	$0.36	$19,999.99	Disclosure SEC source: 0000899243-22-004260 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,433,135 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs are fully vested on January 31, 2022. Read SEC document
November 17, 2021 Filed Nov 22, 2021 09:11 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantStock Option (right to buy) · Derivative	9,653	$0.00 Strike: $3.59	$0.00	Disclosure SEC source: 0001415889-21-005359 · form4-11222021_061130.xml · derivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,653 Underlying: Common Stock · 9,653 shares Expires 2031-11-17 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
November 17, 2021 Filed Nov 22, 2021 09:11 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantCommon Stock, par value $.0001	6,963	$0.00	$0.00	Disclosure SEC source: 0001415889-21-005359 · form4-11222021_061130.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,706 F1 · shares: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
October 29, 2021 Filed Nov 2, 2021 16:49 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	26,888	$0.00	$0.00	Disclosure SEC source: 0000899243-21-042387 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,376,797 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs are fully vested on October 29, 2021. Read SEC document
July 30, 2021 Filed Aug 3, 2021 16:05 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	21,978	$0.91	$19,999.98	Disclosure SEC source: 0000899243-21-031259 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,349,909 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs are fully vested on July 30, 2021. F2 · balance_after: The number of shares beneficially owned has been adjusted pursuant to an internal review of the Reporting Person's holdings. Read SEC document
June 01, 2021 Filed Jun 4, 2021 16:26 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantEmployee stock option (right to buy) · Derivative	31,862	$0.00 Strike: $1.02	$0.00	Disclosure SEC source: 0000899243-21-022031 · doc4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,862 Underlying: Common Stock · 31,862 shares Expires 2021-06-01 F1 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date. Read SEC document
April 30, 2021 Filed May 4, 2021 18:44 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	16,529	$1.21	$20,000.09	Disclosure SEC source: 0000899243-21-018235 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,176,416 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs are fully vested on April 30, 2021. F2 · balance_after: The number of shares beneficially owned has been adjusted pursuant to an internal review of the Reporting Person's holdings. Read SEC document
January 29, 2021 Filed Feb 2, 2021 18:52 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	8,928	$0.00	$0.00	Disclosure SEC source: 0000899243-21-004269 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,157,804 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vested on January 29, 2021. Read SEC document
January 20, 2021 Filed Jan 22, 2021 17:05 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	GrantStock Option (right to buy) · Derivative	49,000	$0.00 Strike: $4.44	$0.00	Disclosure SEC source: 0001250853-21-000018 · primary_doc.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 49,000 shares Expires 2031-01-19 F1 · derivative.exercise_date: The option will vest in four equal quarterly installments from the option grant date. Read SEC document
January 15, 2021 Filed Jan 19, 2021 16:40 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	OtherClass A Warrant · Derivative	41,216	$0.00 Strike: $2.27	$0.00	Disclosure SEC source: 0001638599-21-000068 · doc4_7003.xml · derivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,216 shares Expires 2021-03-24 F1 · derivative.exercise_price: The exercise price per share of the Issuer's common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events. F2 · derivative.underlying_shares: The number of shares of Issuer common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events. F2 · balance_after: The number of shares of Issuer common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events. Read SEC document
January 15, 2021 Filed Jan 19, 2021 16:40 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	OtherCommon Stock, par value $.0001	41,216	$2.27	$93,560.32	Disclosure SEC source: 0001638599-21-000068 · doc4_7003.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,743 Read SEC document
January 08, 2021 Filed Jan 12, 2021 21:23 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantEmployee stock option (right to buy) · Derivative	40,000	$0.00 Strike: $2.24	$0.00	Disclosure SEC source: 0000899243-21-001714 · doc4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-01-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall be deemed vested on the Transaction Date (which is January 8, 2021). Read SEC document
October 30, 2020 Filed Nov 3, 2020 19:10 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	10,057	$1.74	$17,499.18	Disclosure SEC source: 0000899243-20-030309 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,876 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on October 30, 2020. Read SEC document
September 11, 2020 Filed Sep 15, 2020 16:18 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantStock Option (right to buy) · Derivative	9,820	$0.00 Strike: $3.43	$0.00	Disclosure SEC source: 0001104659-20-105238 · tm2030853d6_4.xml · derivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,820 Underlying: Common Stock · 9,820 shares Expires 2030-09-11 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of September 11, 2021 or the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
September 11, 2020 Filed Sep 15, 2020 16:18 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantCommon Stock, par value $.0001	7,288	$0.00	$0.00	Disclosure SEC source: 0001104659-20-105238 · tm2030853d6_4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,527 F1 · shares: Represents restricted stock units that vest on the earlier of September 11, 2021 or the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
July 31, 2020 Filed Aug 3, 2020 17:41 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	10,174	$1.72	$17,499.28	Disclosure SEC source: 0000899243-20-021015 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,174 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on July 31, 2020. Read SEC document
May 18, 2020 Filed May 20, 2020 18:04 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantEmployee stock option (right to buy) · Derivative	9,530	$0.00 Strike: $3.41	$0.00	Disclosure SEC source: 0000899243-20-013727 · doc4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,530 Underlying: Common Stock · 9,530 shares Expires 2030-05-18 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is May 18, 2020) or the day before the 2020 Annual Shareholder Meeting, whichever is earlier. Read SEC document
April 30, 2020 Filed May 4, 2020 21:43 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	5,738	$3.05	$17,500.90	Disclosure SEC source: 0000899243-20-011971 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,738 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on April 30, 2020. Read SEC document
March 24, 2020 Filed Mar 26, 2020 18:12 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	PurchaseClass B Warrant · Derivative	61,823	Not disclosed Strike: $2.72	Not disclosed	Disclosure SEC source: 0001638599-20-000345 · doc4_6614.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,823 Underlying: Common Stock · 61,823 shares Expires 2025-03-24 F3 · derivative.exercise_price: The exercise price per share of the Issuer's common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events. F4 · shares: The number of shares of Issuer common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events. F1 · price: On March 24, 2020, the Reporting Person purchased Units from the Issuer in a private placement, with each Unit consisting of (a) one share of the Issuer's common stock, (b) a Class A Warrant representing the right to acquire 0.5 shares of the Issuer's common stock and (c) a Class B Warrant representing the right to acquire 0.75 shares of the Issuer's common stock. The purchase price for each Unit was $2.42625 of which $2.27 was for the share of the Issuer's common stock, $0.06250 was for the Class A Warrant and $0.09375 was for the Class B Warrant. Read SEC document
March 24, 2020 Filed Mar 26, 2020 18:12 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	PurchaseClass A Warrant · Derivative	41,216	Not disclosed Strike: $2.27	Not disclosed	Disclosure SEC source: 0001638599-20-000345 · doc4_6614.xml · derivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,216 Underlying: Common Stock · 41,216 shares Expires 2021-03-24 F3 · derivative.exercise_price: The exercise price per share of the Issuer's common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events. F4 · shares: The number of shares of Issuer common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events. F1 · price: On March 24, 2020, the Reporting Person purchased Units from the Issuer in a private placement, with each Unit consisting of (a) one share of the Issuer's common stock, (b) a Class A Warrant representing the right to acquire 0.5 shares of the Issuer's common stock and (c) a Class B Warrant representing the right to acquire 0.75 shares of the Issuer's common stock. The purchase price for each Unit was $2.42625 of which $2.27 was for the share of the Issuer's common stock, $0.06250 was for the Class A Warrant and $0.09375 was for the Class B Warrant. Read SEC document
March 24, 2020 Filed Mar 26, 2020 18:12 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	PurchaseCommon Stock, par value $.0001	82,431	$2.27	$187,118.37	Disclosure SEC source: 0001638599-20-000345 · doc4_6614.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,239 F1 · price: On March 24, 2020, the Reporting Person purchased Units from the Issuer in a private placement, with each Unit consisting of (a) one share of the Issuer's common stock, (b) a Class A Warrant representing the right to acquire 0.5 shares of the Issuer's common stock and (c) a Class B Warrant representing the right to acquire 0.75 shares of the Issuer's common stock. The purchase price for each Unit was $2.42625 of which $2.27 was for the share of the Issuer's common stock, $0.06250 was for the Class A Warrant and $0.09375 was for the Class B Warrant. F2 · balance_after: The amount of shares beneficially owned by the Reporting Person has been adjusted to reflect shares of the Issuer's common stock that are no longer beneficially attributed to the Reporting Person since he resigned as trustee of the Mario 2002 Children's Trust. Read SEC document
January 22, 2020 Filed Jan 24, 2020 16:08 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	10,448	$3.35	$35,000.80	Disclosure SEC source: 0000899243-20-001963 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,448 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on January 22, 2020. Read SEC document
January 17, 2020 Filed Jan 22, 2020 18:41 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	GrantStock Option (right to buy) · Derivative	49,000	$0.00 Strike: $9.84	$0.00	Disclosure SEC source: 0001250853-20-000026 · primary_doc.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 49,000 shares Expires 2030-01-16 F1 · derivative.exercise_date: The option will vest in four equal quarterly installments from the option grant date. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	4,756	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001367 · form4-11222019_071129.xml · derivative · entry 10 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,756 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	970	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001367 · form4-11222019_071129.xml · derivative · entry 9 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 970 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	300	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001367 · form4-11222019_071129.xml · derivative · entry 8 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	13,266	$0.00 Strike: $77.38	$0.00	Disclosure SEC source: 0001415889-19-001367 · form4-11222019_071129.xml · derivative · entry 7 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	10,500	$0.00 Strike: $121.04	$0.00	Disclosure SEC source: 0001415889-19-001367 · form4-11222019_071129.xml · derivative · entry 6 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	11,000	$0.00 Strike: $99.98	$0.00	Disclosure SEC source: 0001415889-19-001367 · form4-11222019_071129.xml · derivative · entry 5 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2026-06-15 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $112.16	$0.00	Disclosure SEC source: 0001415889-19-001367 · form4-11222019_071129.xml · derivative · entry 4 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-17 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	20,700	$0.00 Strike: $88.50	$0.00	Disclosure SEC source: 0001415889-19-001367 · form4-11222019_071129.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,700 shares Expires 2024-07-01 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerCommon Stock	4,908	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001367 · form4-11222019_071129.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerCommon Stock	62,884	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001367 · form4-11222019_071129.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document
August 16, 2019 Filed Aug 20, 2019 17:21 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantStock Option (right to buy) · Derivative	9,057	$0.00 Strike: $3.11	$0.00	Disclosure SEC source: 0001638599-19-000794 · doc4_6256.xml · derivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,057 Underlying: Common Stock · 9,057 shares Expires 2029-08-16 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of August 16, 2020 or the date of the Issuer's 2020 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
August 16, 2019 Filed Aug 20, 2019 17:21 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	GrantCommon Stock, par value $.0001	8,038	$0.00	$0.00	Disclosure SEC source: 0001638599-19-000794 · doc4_6256.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,779 F1 · shares: Represents restricted stock units that vest on the earlier of August 16, 2020 or the date of the Issuer's 2020 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document
July 11, 2019 Filed Jul 15, 2019 17:46 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	PurchaseCommon Stock, par value $.0001	35,971	$2.78	$99,999.38	Disclosure SEC source: 0001638599-19-000655 · doc4_6179.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,741 Read SEC document
June 15, 2019 Filed Jun 17, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	375	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000730 · form4-06172019_040624.xml · derivative · entry 7 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F4 · derivative.exercise_date: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F4 · derivative.expiration_date: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document
June 15, 2019 Filed Jun 17, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	375	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000730 · form4-06172019_040624.xml · nonDerivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.